Zacks Investment Research downgraded shares of Odonate Therapeutics (NASDAQ:ODT) from a buy rating to a hold rating in a research note released on Tuesday, Zacks.com reports.

According to Zacks, “Odonate Therapeutics, LLC is a pharmaceutical company. It engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer. Odonate Therapeutics, LLC is based in SAN DIEGO, United States. “

Separately, ValuEngine lowered shares of Odonate Therapeutics from a hold rating to a sell rating in a report on Wednesday, October 2nd.

NASDAQ:ODT traded up $0.97 during trading hours on Tuesday, reaching $33.10. 98,400 shares of the company were exchanged, compared to its average volume of 112,896. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -9.09 and a beta of 1.83. Odonate Therapeutics has a 52-week low of $11.54 and a 52-week high of $43.75. The stock has a 50 day simple moving average of $29.21 and a 200 day simple moving average of $29.63.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its holdings in shares of Odonate Therapeutics by 106.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,703 shares of the company’s stock valued at $63,000 after buying an additional 880 shares during the period. Meeder Asset Management Inc. lifted its position in Odonate Therapeutics by 198.7% in the 2nd quarter. Meeder Asset Management Inc. now owns 1,574 shares of the company’s stock valued at $57,000 after purchasing an additional 1,047 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Odonate Therapeutics by 2.1% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 55,205 shares of the company’s stock valued at $2,026,000 after purchasing an additional 1,150 shares during the last quarter. Chartwell Investment Partners LLC lifted its position in Odonate Therapeutics by 6.2% in the 2nd quarter. Chartwell Investment Partners LLC now owns 30,543 shares of the company’s stock valued at $1,121,000 after purchasing an additional 1,782 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Odonate Therapeutics by 109.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,351 shares of the company’s stock valued at $196,000 after purchasing an additional 2,800 shares during the last quarter. 96.64% of the stock is owned by institutional investors and hedge funds.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Recommended Story: Different Options Trading Strategies

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.